Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
367 stopped studies mapped to Head and Neck Carcinoma and descendants · 94% state a reason
Over the 367 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | Phase 2 | terminated | Jan 27, 2020 | H. Lee Moffitt Cancer Center and Research Institute | Lack of Interest | Other (stated, no rule matched) |
| NCT01891695 | OPSCC N0 Nodal Control With Reduced IMRT | N/A | terminated | Jul 3, 2013 | Paul W. Read, MD | Study had very specific inclusion/exclusion criteria and difficult to recruit | Enrollment / accrual |
| NCT02295540 | Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced… | N/A | withdrawn | Nov 20, 2014 | Rutgers, The State University of New Jersey | slow accrual | Enrollment / accrual |
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic… | N/A | terminated | Feb 16, 2015 | Icahn School of Medicine at Mount Sinai | No Current Funding | Funding |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT03862066 | Memory Phenotype and PD-1 Inhibition Response in Oral Cancer | — | terminated | Mar 5, 2019 | Medical University of South Carolina | Low accrual progress per internal scientific review committee | Enrollment / accrual |
| NCT04831450 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | withdrawn | Apr 5, 2021 | University of Miami | Investigator Decision | Investigator |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | Phase 2 | withdrawn | Jun 28, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sponsor withdrew funding | Funding |
| NCT03720158 | Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of… | N/A | terminated | Oct 25, 2018 | Coordinación de Investigación en Salud, Mexico | The activities in the study hospital were seriously impacted by the medical care of COVID patients,… | COVID-19 / pandemic |
| NCT02325349 | PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During…(MLAPOCHI) | Phase 2 | terminated | Dec 25, 2014 | Assistance Publique - Hôpitaux de Paris | Change in protocol strategy | Sponsor / business decision |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT04849377 | RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC | Phase 2 | withdrawn | Apr 19, 2021 | Icahn School of Medicine at Mount Sinai | lack of eligible participants due to change in study criterias | Other (stated, no rule matched) |
| NCT03090412 | Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients… | Phase 2 | terminated | Mar 24, 2017 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT04003025 | Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC)(HNCAX01) | — | withdrawn | Jul 1, 2019 | Instituto do Cancer do Estado de São Paulo | The proposed analysis was not feasible. | Other (stated, no rule matched) |
| NCT04272333 | Intratumoral Microdosing of Motolimod in HNSCC | Early Phase 1 | terminated | Feb 17, 2020 | Presage Biosciences | Partner Termination | Other (stated, no rule matched) |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2022 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT04428047 | Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell…(ICING) | Phase 2 | terminated | Jun 11, 2020 | UNICANCER | Sponsor decision following information on cases of hyperprogression and early toxicities with… | Safety / toxicity |
| NCT04266470 | Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region | N/A | withdrawn | Feb 12, 2020 | Wake Forest University Health Sciences | Study is no longer feasible at our site. | Other (stated, no rule matched) |
| NCT03745690 | Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients… | Phase 1 / Phase 2 | withdrawn | Nov 19, 2018 | Jonsson Comprehensive Cancer Center | no enrollment | Enrollment / accrual |
| NCT04832438 | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma | Phase 2 | withdrawn | Apr 5, 2021 | Actuate Therapeutics Inc. | Replaced by NCT05010629 | Other (stated, no rule matched) |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT04129320 | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | Phase 2 / Phase 3 | withdrawn | Oct 16, 2019 | MacroGenics | Change in study design | Other (stated, no rule matched) |
| NCT05099952 | Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients | N/A | withdrawn | Oct 29, 2021 | Roswell Park Cancer Institute | PI left institute-no accruals | Investigator |
| NCT02901483 | A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for… | Phase 1 / Phase 2 | terminated | Sep 15, 2016 | PharmaEngine | bussiness reason | Other (stated, no rule matched) |
| NCT02289807 | Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated… | N/A | withdrawn | Nov 13, 2014 | Sun Yat-sen University | not stated | Not stated |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced… | Phase 1 / Phase 2 | terminated | Aug 9, 2019 | Pfizer | Study prematurely terminated as the experimental treatments evaluated in study B9991040 may not… | Other (stated, no rule matched) |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | Phase 2 | withdrawn | Feb 12, 2019 | Antonio Fojo | Closed by sponsor | Other (stated, no rule matched) |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid… | Phase 1 / Phase 2 | terminated | Apr 27, 2017 | Dana-Farber Cancer Institute | Study closed due to slow accrual and lack of efficacy. | Efficacy / futility |
| NCT02952586 | Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC… | Phase 3 | terminated | Nov 2, 2016 | Pfizer | The trial prematurely terminated as recommended by the E-DMC because the boundary for futility has… | Efficacy / futility |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT01967927 | Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial… | Early Phase 1 | withdrawn | Oct 23, 2013 | University of Arkansas | Study has been open for 8 years with no enrollment. Procedures in 2013 protocol are outdated.… | Enrollment / accrual |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | Phase 2 | terminated | Aug 14, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Lack of efficacy | Efficacy / futility |
| NCT03463889 | Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid… | Phase 2 | terminated | Mar 13, 2018 | University of California, San Francisco | Funding | Funding |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03673735 | Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in…(ADHERE) | Phase 3 | withdrawn | Sep 17, 2018 | European Organisation for Research and Treatment of Cancer - EORTC | Company withdrew interest | Sponsor / business decision |
| NCT03390738 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2… | Phase 2 | withdrawn | Jan 4, 2018 | The University of Hong Kong | Sponsor withdrew funding for Nivolumab | Funding |
| NCT00492947 | Dendritic Cell Vaccine for Head and Neck Cancer(Dendritic) | Phase 1 | withdrawn | Jun 27, 2007 | University of Maryland, Baltimore | major amendments in progress | Other (stated, no rule matched) |
| NCT02177838 | Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck… | N/A | terminated | Jun 30, 2014 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT01707056 | The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid… | N/A | withdrawn | Oct 15, 2012 | Medstar Health Research Institute | not stated | Not stated |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck… | Phase 1 / Phase 2 | terminated | May 18, 2012 | Novartis Pharmaceuticals | early termination due to Sponsor decision (slow recruitment) | Enrollment / accrual |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell… | Phase 1 / Phase 2 | terminated | Aug 31, 2018 | Washington University School of Medicine | Provider of drug decided to discontinue study. | Other (stated, no rule matched) |
| NCT04262388 | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab…(DOME) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic… | Phase 2 | withdrawn | Jan 18, 2020 | Alain Algazi | Feasibility | Other (stated, no rule matched) |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 16, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03276819 | A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML…(UMBRELLA) | N/A | terminated | Sep 8, 2017 | Centre Leon Berard | Early termination of the study, since July 31, 2020 for insufficient recruitment | Enrollment / accrual |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | Phase 1 / Phase 2 | terminated | Jan 29, 2008 | Daiichi Sankyo | Due to low enrollment, no participant had a dose limiting toxicity, therefore a maximum tolerated… | Safety / toxicity |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or… | Phase 2 | withdrawn | Sep 27, 2019 | M.D. Anderson Cancer Center | No Participants Registered | Other (stated, no rule matched) |
| NCT04093115 | Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | Phase 2 | withdrawn | Sep 17, 2019 | Beijing Konruns Pharmaceutical Co., Ltd. | The study was terminated voluntarily by the sponsor due to changes in clinical development strategy. | Sponsor / business decision |
| NCT02464137 | HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer(HYDRA) | Phase 1 | terminated | Jun 8, 2015 | University of Texas Southwestern Medical Center | unexpected toxicities | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 4, 2022source: clinicaltrials